Overview

The Effect of Remimazolam on Opioid Induced Hyperalgesia

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:
0

Participant gender:
All

Summary

The goal of this prospective, randomized, controlled study is to investigate the effect of remimazolam on opioid-induced hyperalgesia (OIH) in patients undergoing single port-laparoscopically assisted urologic surgery. The main question[s] it aims to answer are: - [The mechanical hyperalgesia threshold] - [Area of hyperalgesia around the surgical incision 24 h after surgery (cm^2)] In three groups: Group RHR (Remimazolam- High-dose Remifentanil), Group DHR (Desflurane-low-dose Remifentanil) or Group DLR (Control).

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Wonkwang University Hospital

Treatments:

Desflurane
Remifentanil

Criteria

1. Inclusion criteria will include as follows; ASA(American Society of
Anesthesiologists)physical status 1-2 patients, Age with 20-65 years, and Single
port-laparoscopically assisted urologic surgery.

2. Exclusion criteria will include as follows; a known allergy to remimazolam or
remifentanil, a history of drug or alcohol abuse, psychiatric disorders, acute
cardiovascular disorders, or unstable hypertension, and other respiratory or
neuromuscular pathology, treated with opioid-containing any analgesic drug within 24 h
before surgery and contraindications to the self-administration of opioids (i.e., were
unable to understand the PCA device).